Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.00% | 5.14% | 6.49% | 1.73% | 1.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00% | 5.14% | 6.49% | 1.73% | 1.08% |
| Cost of Revenue | 6.14% | 14.82% | -11.80% | -7.67% | -27.65% |
| Gross Profit | 4.71% | 2.52% | 11.97% | 4.84% | 12.46% |
| SG&A Expenses | 8.26% | 27.63% | 23.49% | 30.02% | 20.48% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.23% | 26.29% | 13.46% | 16.95% | 5.98% |
| Operating Income | -40.90% | -107.82% | -40.08% | -70.51% | -48.22% |
| Income Before Tax | -42.59% | -97.76% | 106.86% | -105.27% | -36.17% |
| Income Tax Expenses | -46.53% | -111.24% | -11.24% | -83.50% | -16.46% |
| Earnings from Continuing Operations | -39.40% | -89.79% | 103.79% | -125.66% | -46.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.40% | -89.79% | 103.79% | -125.66% | -46.41% |
| EBIT | -40.90% | -107.82% | -40.08% | -70.51% | -48.22% |
| EBITDA | -10.48% | -51.68% | -31.65% | -26.85% | -13.56% |
| EPS Basic | -30.67% | -88.92% | 103.96% | -126.06% | -46.14% |
| Normalized Basic EPS | -69.94% | -114.46% | -19.90% | -104.13% | -33.13% |
| EPS Diluted | -30.00% | -88.38% | 103.86% | -128.29% | -47.84% |
| Normalized Diluted EPS | -70.05% | -115.17% | -20.65% | -104.53% | -25.36% |
| Average Basic Shares Outstanding | -12.56% | -7.97% | -4.54% | -1.55% | -0.48% |
| Average Diluted Shares Outstanding | -12.07% | -12.35% | -3.63% | -10.05% | -10.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |